BT
Bonum Therapeutics, Inc.
SEC filingBiotechnology · Seattle, WA
Amount raised$26.9Msold at filing
Total offering$32.3M$5.4M still open
Investors in the raise8count reported to the SEC
FiledApr 17, 2026first sale Apr 3, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Samuel BjorkDirector
Monique SchiersingDirector
Neela PatelExecutive Officer
John McKearnDirector
Diane HollenbaughExecutive Officer
Samuel BlackmanDirector
John MulliganExecutive Officer, Director, Promoter
Karl HandelsmanDirector
Nicholas WalrodDirector
Mitchell MutzDirector
Gaurav AggarwalDirector
Executive officers, directors and promoters as listed on the Form D.